References
- Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomised, double-blind study. AIDS 2002; 16: 1257–63.
- Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal anion transporter 1. J Am Soc Nephrol 2000; 11: 383–93.
- Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiretroviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001; 20: 641–8.
- Cheng A, Coakley D, Chen SS, Wulfsohn M, Toole JJ. Safety profile of tenofovir DF in treatment-experienced patients from randomised, placebo-controlled clinical trials. Poster 4460. XIV International AIDS Conference, Barcelona, 2002.
- Flaherty JF, Kearney BP, Wolf JJ, Sayre JR, Coakley DF. A multiple-dose, randomized study between tenofovir DF and efavirenz, indinavir or lopinavir/ritonavir. Poster 336. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.